ReviewEuropean radiology2026
Photon-counting CT in neuroradiology: a comprehensive SWOT analysis.
Review in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photon-counting-detector computed tomography (PCD-CT) is a disruptive technology in neuroradiology, as evidenced by the unprecedented excitement surrounding its potential clinical applications and the field's growing number of publications. By employing photon-counting detectors capable of capturing information about individual photons and measuring their energy levels, PCD-CT offers benefits over conventional energy-integrating detector (EID) CT, including a higher contrast-to-noise ratio, reduced metal artifacts, improved spatial resolution, and decreased radiation and iodine dose necessary to achieve the highest resolution images seen to date. The currently available whole-body clinical PCD-CT scanner applications in neuroradiology range from optimized bone assessment to discrimination of fine details in neurovascular evaluation. However, intrinsic barriers such as cost and technical complexity, and external factors, including a lack of protocol standardization and direct competition with other technologies, hinder the widespread adoption of PCD-CT. To analyze the current state of evidence for PCD-CT in neuroradiology, we conducted a SWOT (Strengths, Weaknesses, Opportunities, and Threats) analysis, which may help readers and researchers to make a picture of this disruptive technology. KEY POINTS: Question A SWOT analysis of PCD-CT in neuroradiology may be useful to objectively assess its technical strengths, implementation challenges, opportunities, and threats for clinical adoption. Findings Photon-counting detector CT demonstrates superior spatial resolution, reduced artifacts, and lower radiation doses compared to conventional CT, enhancing neuroradiological imaging quality. Clinical relevance PCD-CT offers enhanced diagnostic accuracy and safety in neuroradiology, enabling better visualization of fine structures and vascular abnormalities while minimizing radiation exposure and reducing contrast agent requirements for sensitive populations.
Indexed as
Identifiers
41417119What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.